If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a roadblock for his company’s medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy.
If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a roadblock for his company’s medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy.
